Brain tumor patients get infused with a genetically altered herpes virus

NCT ID NCT06126744

Recruiting now Disease control Sponsor: Duke University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage trial is testing a specially designed herpes virus, MVR-C5252, that is injected directly into brain tumors in people whose high-grade glioma has returned. The virus is modified to attack cancer cells and boost the immune system. The main goal is to see if it is safe and to find the best dose, with a later stage checking if it helps control the cancer.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: MVR-C5252 (a modified herpes simplex virus 1 that carries immune-boosting components)
What this could lead to: If this works, it could point toward a new way to treat aggressive brain cancers that have come back after standard therapy.
What could go wrong: This is a very early Phase 1 trial with only 51 people, focused on safety. The virus may not shrink tumors or improve survival, and there are risks from the injection and the virus itself.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RECURRENT GLIOBLASTOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

glioblastoma glioma malignant glioma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RECURRENT HIGH GRADE GLIOMA

Contacts and locations

Locations

Duke University
RECRUITING

Durham, North Carolina, 27750, United States
Memorial Sloan Kettering
RECRUITING

New York, New York, 10065, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.